41 results about "Mononucleosis" patented technology

The invention relates to the field of gene engineering, and aims to provide a construction method and application of attenuated Listeria monocytogenes. A Listeria monocytogenes wild strain EGD-e is used as a construction parent, and asparagine at the 478th site and valine at the 479th site of an hly gene are respectively mutated into alanine without containing plasmids; the finally obtained attenuated strain is named as Lemo-C07, the preservation number of the attenuated strain is CGMCC 18647, and the preservation institution is China General Microbiological Culture Collection Center. The attenuated strain of Listeria monocytogenes can be used as a live vaccine treatment carrier or an immunologic adjuvant; after amino acid site-specific mutagenesis of the key sites N478 and V479 of the Listeria monocytogenes virulence gene hly, the toxicity of the Listeria monocytogenes is greatly reduced (reaching a safety level), but very good immunogenicity is still retained. As direct mutation is carried out on the Listeria monocytogenes genome, the Listeria monocytogenes does not contain resistance plasmids, the biosafety is met, and the growth of the Listeria monocytogenes is not influenced by the loss of the plasmids.

Vital mononucleosis listeria RT-PCR fast inspecting reagent kit and its method are disclosed. The process is carried out by taking mRNA of mononucleosis listeriolysin gene hlyA as target, extracting sample RNA, RT-PCR amplification reacting and electrophoresis inspecting. It is fast, has better sensitivity and operability. It can be used in environmental inspection, food production and commodity quarantine.

The present invention relates to compositions comprising a lipophilic local anaesthetic, preferably bupivacaine or a pharmaceutically active salt thereof, which are formulated for local administration to the mouth or throat of a subject. The compositions are useful in the treatment or alleviation of pain, burning or xerostomia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa or for use in providing local anesthesia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa. In particular in the treatment of pain, burning or xerostomia, which is caused by a disease such as oral mucositis, Burning Mouth Syndrome, Sjogren's syndrome, xerostomia, periodontitis, toothache, tonsillectomy, throat infection or mononucleosis, canker sores and aphthous stomatitis.

A Lister bacterium and fast test reagent kit are disclosed. It consists of two freezing tubes containing different ingredients, 100 PCR reactive tubes and test specifications, the freezing tubes include TaqDNApolymerase, 10Xbuffer, dNTP, primer LM, LN, LS, LVSW, LGU, Ld, Lmo0038-1 and Lmo0038-2 and cracking buffer solution, positive control solution and diluting solution. The lowest testing limitreaches to 102FU / mL is correct, specific and sensitive.

Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and / or reduce the risk of EBV infection and to treat and / or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

The present invention provides EBNA1 inhibitors, and / or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and / or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and / or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and / or lytic EBV infection.

The invention relates to the use of an EBV membrane antigen or derivative thereof in combination with a suitable adjuvant in the manufacture of a vaccine for the prevention of infectious mononucleosis (IM), and to vaccine compositions suitable for prevention of IM.

The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and / or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.